BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36397716)

  • 1. Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.
    Patel N; Hakansson A; Ohtake S; Muraki P; Proudfout JA; Liu Y; Webber L; Ibarra A; Liu VYT; Davicioni E; Chamie K; Pantuck A; Shuch B
    Cancer Med; 2023 Mar; 12(5):6437-6444. PubMed ID: 36397716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study.
    Yang G; Nie P; Yan L; Zhang M; Wang Y; Zhao L; Li M; Xie F; Xie H; Li X; Xiang F; Wang N; Cheng N; Zhao X; Wang N; Wang Y; Chen C; Yun C; Cui J; Duan S; Zhang R; Hao D; Wang X; Wang Z; Niu H
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2949-2959. PubMed ID: 35344062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 5. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
    Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
    Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer.
    El Khoury LY; Fu S; Hlady RA; Wagner RT; Wang L; Eckel-Passow JE; Castle EP; Stanton ML; Thompson RH; Parker AS; Ho TH; Robertson KD
    Clin Epigenetics; 2021 Jan; 13(1):12. PubMed ID: 33461589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
    Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
    Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
    BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
    Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
    JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preoperative CT-based deep learning radiomics model in predicting the stage, size, grade and necrosis score and outcome in localized clear cell renal cell carcinoma: A multicenter study.
    Nie P; Liu S; Zhou R; Li X; Zhi K; Wang Y; Dai Z; Zhao L; Wang N; Zhao X; Li X; Cheng N; Wang Y; Chen C; Xu Y; Yang G
    Eur J Radiol; 2023 Sep; 166():111018. PubMed ID: 37562222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
    Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
    J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
    Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
    Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
    Liu W; Liu Y; Fu Q; Zhou L; Chang Y; Xu L; Zhang W; Xu J
    Oncotarget; 2016 Mar; 7(12):13976-83. PubMed ID: 26910919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
    Palumbo C; Perri D; Zacchero M; Bondonno G; Martino JD; D'Agate D; Volpe A
    Urol Oncol; 2022 Apr; 40(4):167.e1-167.e7. PubMed ID: 35034803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma.
    Nejati R; Wei S; Uzzo RG; Poureghbali S; Pei J; Talarchek JN; Ruth K; Dulaimi E; Kutikov A; Testa JR; Al-Saleem T
    Clin Genitourin Cancer; 2020 Feb; 18(1):56-61. PubMed ID: 31648964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.